Subscribe To

Price Alert Latest News Economic Calendar News

GNPX / Genprex unveils groundbreaking data from primate study on its novel gene therapy to treat Type 1 diabetes at ATTD 2023 in Berlin

Genprex, Inc. (NASDAQ:GNPX) has announced that data highlighting the potential of its gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh at the four-day International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), which started on February 22, 2023, in Berlin, Germany. The Austin, Texas-based clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes, said the abstract data was released, and the presentation will be delivered on February 25 at 2:25 pm CET by Ranjeet Kalsi, a member of the laboratory of George Gittes, from the University of Pittsburgh's Division of Pediatric Surgery, in Pennsylvania. Read More

Demo Live Account See Partner Details

Content Topics

Genprex

Unveils

Groundbreaking

Data

From

Primate

Study

Novel

Therapy

Diabetes

Berlin

Stock

GNPX

Posted: Feb 23 2023, 08:40

Author Name: Proactive Investors

GNPX News

By Zacks Investment Research
September 4, 2023

GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know

GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st

By Proactive Investors
July 5, 2023

Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers

Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead dru

By Proactive Investors
June 28, 2023

Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA

Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Dru

By Zacks Investment Research
June 1, 2023

Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study

Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.

By Proactive Investors
May 30, 2023

Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancer

Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combi

By Proactive Investors
May 26, 2023

Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting

Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combin

By Proactive Investors
April 19, 2023

Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise

A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the compa

By Proactive Investors
April 18, 2023

Genprex encouraged by latest reports on novel tumor suppressor

Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functio

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.